Breast cancer affects millions worldwide, and genetic factors play a crucial role in determining individual risk and guiding treatment. Approximately 5.3% of women newly diagnosed with breast cancer carry pathogenic variants in genes such as BRCA1, BRCA2, or PALB2, which significantly increase their cancer risk and influence management strategies1 . Jill Martin’s 2023 breast cancer diagnosis highlights the importance of genetic testing, especially for those with a family history, even when standard imaging tests are clear2 .
Genetic Testing and Breast Cancer Risk
Genetic testing identifies pathogenic germline variants—heritable mutations—in genes like BRCA1, BRCA2, and others that substantially elevate breast cancer risk. These mutations can be inherited from either parent, underscoring the need to consider both maternal and paternal family histories3 . For example, Jill Martin inherited a BRCA2 mutation from her father's side, despite her mother testing negative for BRCA mutations4 .
Universal genetic testing programs for women newly diagnosed with breast cancer reveal that about 5.3% carry germline pathogenic variants in BRCA1, BRCA2, or PALB21 . These mutations confer a high lifetime risk of breast cancer, estimated between 60% and 90% for BRCA2 carriers like Jill Martin5 . Importantly, genetic testing now extends beyond BRCA1/2 to include over 20 other genes associated with cancer risk, such as PALB2, CHD1, and TP536 3.
Key points about genetic testing and breast cancer risk include:
- Pathogenic variants in BRCA1/2 and other genes significantly increase breast cancer risk1 .
- Mutations can be inherited from either parent, not just the mother’s side4 .
- Genetic testing panels cover more than 20 genes linked to hereditary cancer risk6 .
- About 5.3% of newly diagnosed breast cancer patients have pathogenic variants in BRCA1/2 or PALB21 .
- Individuals with family histories of breast, ovarian, pancreatic, or prostate cancer should consider genetic testing3 .
Jill Martin’s case exemplifies the limitations of standard imaging. Despite a clean mammogram and sonogram before diagnosis, her preoperative MRI detected an aggressive cancerous mass4 . This underscores the value of genetic testing in identifying high-risk individuals who may benefit from enhanced surveillance or preventive measures.
Impact of Genetic Testing on Patient Management
Genetic testing results directly influence breast cancer treatment decisions and patient management. Women with pathogenic variants in BRCA1/2 and other associated genes are more likely to receive chemotherapy and may have different radiation therapy plans compared to those without such mutations7 . Rapid genetic testing at diagnosis can also affect psychosocial functioning and help patients make informed treatment choices early in their care8 .
Jill Martin’s treatment journey illustrates how genetic findings shape management. After discovering her BRCA2 mutation and cancer diagnosis, she underwent six surgeries, including a double mastectomy and breast reconstruction, followed by chemotherapy and radiation5 4. She also had preventive removal of her ovaries and fallopian tubes to reduce future cancer risk3 . Despite intense treatment, she maintained her professional schedule and used cold cap therapy to mitigate chemotherapy-induced hair loss4 .
Treatment considerations influenced by genetic testing include:
- Increased likelihood of chemotherapy for patients with pathogenic variants7 .
- Possible avoidance or modification of post-lumpectomy radiotherapy based on genetic status7 .
- Use of preventive surgeries such as mastectomy and oophorectomy in mutation carriers3 .
- Psychosocial impacts managed through rapid genetic testing and counseling8 .
- Personalized treatment plans guided by genetic test results9 .
Genetic testing also aids in identifying eligibility for targeted therapies, with about 1.8% of breast cancer patients qualifying based on their genetic profile1 . This precision medicine approach improves outcomes and reduces unnecessary treatments.
Because of her unique diagnosis and complex family history, there were a number of complex decisions to be made where there was no right answer. Her medical oncologist encouraged seeking a second opinion and was very open to getting input from other medical oncologists on the best solutions moving forward. While she didn't seek an 'official' second opinion, she reached out to several colleagues who had special expertise in the thorny areas of making decisions10 .
Seeking a second opinion is often recommended, especially when genetic testing reveals complex risk factors or when initial diagnoses are uncertain. For instance, another breast cancer patient, Robyn Heid, had her diagnosis revised after a second opinion, which altered her treatment and spared her chemotherapy11 10.
Family Communication and Genetic Test Results
Effective communication of genetic test results within families is critical for risk reduction and early cancer detection among relatives. Guidelines from professional societies now recommend broader genetic testing for breast cancer patients, including multigene panels, to better identify hereditary risk12 . After testing, sharing results with family members allows them to pursue appropriate screening or preventive strategies.
Research shows that family communication of genetic test results is more common among younger patients and those with high confidence in managing their health (self-efficacy). Genetic counseling and educational resources, such as family sharing letters and printed materials, support this communication process13 . Jill Martin’s experience underscores the importance of informing relatives, as her family history included her grandmother’s death from breast cancer and her mother’s prior diagnosis, even though her mother tested negative for BRCA mutations5 4.
Genetic testing not only guides treatment but also empowers families to take preventive action. Sharing results with relatives can lead to early screening and risk reduction, potentially saving lives13 4.
Key factors supporting family communication of genetic results include:
- Younger age and high self-efficacy increase likelihood of sharing results13 .
- Genetic counseling improves understanding and facilitates family discussions13 .
- Educational tools like family sharing letters aid communication13 .
- Broader genetic testing panels help identify risks beyond BRCA1/212 .
- Family members can pursue early detection or preventive measures based on shared results13 .
Family communication is essential because hereditary breast cancer accounts for 5–10% of cases, and identifying mutation carriers can prevent late-stage diagnoses4 . Jill Martin’s story also highlights missed opportunities in breast centers to flag high-risk patients for genetic testing, emphasizing the need for improved risk assessment and automated tools to ensure no patients fall through the cracks14 .
